Stock News and Filings Feed
This week, “AstraZeneca Pharma India has received a one month extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India. The parent company has given extension due to delay in the divestment of AstraZeneca’s global rights to Meronem.”
AstraZeneca Pharma India has got another month’s extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India due to delay in the divestment of AstraZeneca’s global rights to Meronem.
AstraZeneca Pharma India has got another month's extension from its parent firm AstraZeneca UK to sell anti-bacterial drug Meronem in India due to delay in the divestment of AstraZeneca's global rights to Meronem.
Key benchmarks ended with minor losses as negative global cues spoiled investors sentiment. The barometer index, the S&P BSE Sensex, fell 13.89 points or 0.04% to 31,283.64, as per the provisional closing data. The Nifty 50 index fell 16.40 points or 0.17% to 9,637.10, as per the provisional closing data.
AstraZeneca Pharma India rose 1.47% to Rs 933 at 11:02 IST on BSE after the company said it received import and market permission in Form 45 from Drug Controller General of India for FDC of inhalation powder.
FDC of Budesonide 320 µg + Formoterol Fumarate Dihydrate 9 µg inhalation powder (Symbicort® Turbuhaler® 320/9 µg) is a product of AstraZeneca global and is indicated in the regular treatment of Asthma where use of combination of inhaled regular corticosteroid & long acting ß-agonist is appropriate and patients with moderate to severe COPD with frequent symptoms and a history of exacerbations
From Thursday, Indian Oil Corporation and Rural Electrification Corporation will be part of the MSCI Global Standard Index while Divi’s Laboratories will be out.
Indian shares continued their record-setting spree on Tuesday, hitting all-time highs for the third time in five sessions, as investors remained bullish about the prospects of a good monsoon.
Shares of Indian Oil Corp Ltd and Rural Electrification Corp rose 1-1.2 per cent, while drug-maker Divi's Laboratories Ltd fell 0.4 per cent.
Drug pricing regulator NPPA has slashed price of cancer drugs by up to 86 per cent since March last year providing relief to lakhs of patients.